Nordic Pharma, a subsidiary of SEVER Life Sciences, is showcasing LACRIFILL Canalicular Gel at the American Academy of Ophthalmology Annual Meeting. This gel is used by over 2,200 US eye care practices to improve recovery after cataract and refractive surgeries and to treat dry eye disease, benefiting over 130,000 patients. Recent surveys show high patient satisfaction, with 96% of recent cataract surgery patients reporting improved eye comfort. The gel also reduces reliance on eye drops and supports long-term ocular surface health post-surgery. Nordic Pharma will demonstrate the product and share new patient data during the event in New Orleans from October 9–12.
The news about SEVER Life Sciences B.V. and its subsidiary Nordic Pharma, Inc. sharing patient data for LACRIFILL Canalicular Gel provides context for readers following health sector stocks. For readers following the health sector, here is Pluang's market snapshot as of Oct 07, 2026 21:21 WIB: out of 100 priced US health-sector stocks, 56 rose and 43 fell. Notable movers include CVS Health Corp at USD 88.77 (+2.70%, with 100% sell order activity), Amgen, Inc. at USD 413.42 (+2.69%, with 60% buy order activity), and Mesoblast Limited at USD 13.97 (+2.65%, typical hold time 14 days).
BNP Paribas lowered Hormel Foods' price target from $26 to $23, indicating a potential 16.2% upside from its current price of around $19.80. Despite a 50.5% decline in its share price over five years, Hormel Foods remains attractive for dividend inve...
Barclays initiated coverage of Becton, Dickinson and Company (BDX) with an "Underweight" rating, indicating a cautious outlook for the medical technology stock. BDX is partnering with the U.S. government to boost domestic manufacturing and strengthen...
Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...
Arthur J. Gallagher expects about 6% organic growth in Q3, driven by strong client retention and new business despite easing property insurance pricing. Cantor Fitzgerald lowered its price target to $280, below the $288 average from 19 analysts who m...
Needham raised Zscaler's price target to $255, citing strong demand for AI-related cybersecurity solutions. Zscaler aims to exceed $8 billion in annual recurring revenue by fiscal 2031, driven by increasing needs to protect against AI-powered cyberat...
